Gastrointestinal Malignancies

The coverage of the series will encompass reviews of advances in therapeutics in all the major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact, and encompassing new technologies with implications for management such as molecular imaging. Features of "The Emerging Cancer Therapeutics" include: each volume is focused on a major topic area within cancer therapeutics. The articles include coverage of clinical and translational research developments as well as clinical applications and experience. The articles provide authoritative analyses that are timely yet more in-depth than the typical journal review article. The emphasis is on review of recent evidence and outcomes data. Gastrointestinal (GI) cancers are common diseases worldwide. About 400,000 patients are diagnosed with esophageal cancer worldwide each year and nearly 330,000 die for this disease. Roughly 870,000 patients are newly diagnosed each year with gastric cancer and over 600,000 die from the disease each year. And 940,000 new cases of colorectal cancer are diagnosed annually and 490,000 patients die from this disease. Management options for patients with GI cancer have undergone dramatic changes in the past decade. New cytotoxic agents, novel targeted agents, surgical and ablative options, as well as a new array of supportive medications have shown substantial progress. With the increased number of therapeutic options from which to choose, the clinician is better placed to offer effective therapy. At the same time the clinician is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the options for treatment today and in the future. "Gastrointestinal Malignancies" provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers